Acadia Healthcare Company, Inc.
ACHCAcadia Healthcare Company, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +27.2% in a year while annual EPS moved −537.4% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (7 weeks in) while the P/E sits at the 55th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit −100.0% year on year, and 168% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Acadia Healthcare Company, Inc. trades at $28.2, in a confirmed uptrend and 7 weeks into that stage. That is +20.4% against its own 200-day average. It sits at 72% of a 52-week range of $12 to $35. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 13 straight weeks.
Today the stock is in a confirmed uptrend — week 7 of stage 2. At $28.2 it trades +20.4% versus its 200-day average and sits at 72% of its 52-week range ($12–$35).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved −48% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 13 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Acadia Healthcare Company, Inc. trades at 23.8× P/E, mid-range by its own standards (55th percentile). Its long-run median P/E is 23.4×, measured across 4.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 23.8× is mid-range by its own standards (55th percentile), against a long-run median of 23.4× measured over 4.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −537.4% against a +27.2% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the −26.2%/yr price move, ~−27.3%/yr came from earnings growth and ~+1.1 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Acadia Healthcare Company, Inc. reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −678.9% latest against −22.9% at its 12-quarter best), ROCE slipping at 4.8%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +5.1% | +8.2% | — | — |
| Stock price | +27.2% | −26.2% | −14.4% | −5.9% |
4-Factor Sector Score
42.8/100 — rank 22 of 30 in Medical Care Facilities · 58% evidence confidence
Acadia Healthcare Company, Inc. scores 42.8 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 22. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 15.1 + 7.5 + 9.5 + 10.7 = 42.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Acadia Healthcare Company, Inc. reported $0.8 B of revenue in the Mar 26 quarter, +7.8% year on year. That is the 4th straight quarter of year-on-year growth. Over 4 years it has compounded at 9.4% a year. The last full year, FY25, came in at $3.3 B. The last four reported quarters add to $3.4 B.
FY25 revenue came in at $3.3 B (+5.1% on the year), capping 4 years at 9.4% compound. The latest quarter (Mar 26) printed $0.8 B, +7.8% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +6.7% growth against the decade's 9.4% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +6.6% over the last 4 quarters against +6.2%/yr over the last 8 — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Acadia Healthcare Company, Inc.'s operating margin is 6.0% in the Mar 26 quarter, +0.8 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −28.1% to 16.1%. The current quarter sits inside that band.
The latest quarter's operating margin is 6.0%, +0.8 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −28.1%–16.1%.
Why the margin moved: operating margin went +0.8 pp year on year while gross margin went +0.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Acadia Healthcare Company, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −100.0% year on year. The full FY25 year was a loss of $1.1 B. That is 0.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 2 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.0 B, −100.0% year on year. On the full year, FY25 printed $−1.1 B (−519.2%).
🚨 Why profit moved: revenue contributed +7.8% and the margin +0.8 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −1,056.5% vs revenue +6.7%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 168% of Acadia Healthcare Company, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.1 B of operating cash against $−1.1 B of profit. After $0.6 B of capital spending, $−0.4 B was left as free cash.
FY25: operating cash of $0.1 B against reported profit of $−1.1 B, leaving free cash of $−0.4 B after $0.6 B of capital spending. Across the last 3 fiscal years the conversion rate is 168% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Acadia Healthcare Company, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $2.0 B over the last 3 years. Averaged over those years that is 20.1% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $2.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Acadia Healthcare Company, Inc. earns a ROE of −51% in FY25. Return on invested capital clears the cost of that capital by +1.1 percentage points, so growth here adds value rather than only size. The wiring behind it is −32.9% net margin on 0.60× asset turns.
FY25 ROE is −51%.
Why the return is what it is — the wiring (FY25): −32.9% net margin × 0.60× asset turns × 2.58× balance-sheet leverage ≈ −50.9% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 7.3% − 6.2% = a +1.1 pp spread. The 6.2% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend
Acadia Healthcare Company, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Acadia Healthcare Company, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Acadia Healthcare Company, Inc. carries total debt of $2.6 B against shareholder equity of $2.2 B as of Jun 26, a debt-to-equity of 1.17. On the annual view that ratio went from 0.64 in FY21 to 1.23 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $2.6 B against shareholder equity of $2.2 B — a debt-to-equity of 1.17. On the annual view, debt-to-equity went from 0.64 (FY21) to 1.23 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
24.7% of Acadia Healthcare Company, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 12.7 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 24.7% of the float is sold short, and at typical trading volumes it would take about 12.7 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Acadia Healthcare Company, Inc.: the Z-score reads 1.04. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 1.04 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 1.04.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Tenet Healthcare CorporationTHC | 65.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 24.1/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence | 16.4/25 ROCE 5.8% · OPM 23.2% 76% evidence | 11.0/20 P/E 7.2× · PEG — 15% evidence | 13.7/20 RS sector -3.7% · RS bench 18.8% · 1Y 39.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 24.1 + 16.4 + 11 + 13.7 = 65.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Concentra Group Holdings Parent, Inc.CON | 62.0/100Mixed-positive evidence71% evidence | LEADER | 19.8/35 Revenue 15.5% · PAT 12.9% · OPM change 0.8 pp 83% evidence | 14.7/25 ROCE 3.8% · OPM 16.8% 76% evidence | 10.1/20 P/E 15.4× · PEG — 15% evidence | 17.4/20 RS sector 13.5% · RS bench 38% · 1Y 76%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 14.7 + 10.1 + 17.4 = 62 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Encompass Health CorporationEHC | 61.5/100Mixed-positive evidence81% evidence | BREAKING OUT | 20.8/35 Revenue 10.1% · PAT 21% · OPM change 0.7 pp 83% evidence | 15.8/25 ROCE 4.9% · OPM 19% 76% evidence | 14.0/20 P/E 16.1× · PEG 0.68 65% evidence | 10.9/20 RS sector -15.3% · RS bench 5.4% · 1Y -0.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 15.8 + 14 + 10.9 = 61.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Addus HomeCare CorporationADUS | 56.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 21.2/35 Revenue 19.5% · PAT 26.6% · OPM change 0.4 pp 83% evidence | 12.3/25 ROCE 2.7% · OPM 9.4% 76% evidence | 13.4/20 P/E 17.3× · PEG 0.78 65% evidence | 10.0/20 RS sector -17.2% · RS bench 3% · 1Y 5.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 12.3 + 13.4 + 10 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Nutex Health Inc.NUTX | 55.9/100Mixed-positive evidence75% evidence | LEADER | 17.5/35 Revenue 40.8% · PAT 31.3% · OPM change -0.6 pp 83% evidence | 15.9/25 ROCE 12.1% · OPM 37.5% 76% evidence | 6.8/20 P/E 6.9× · PEG 2.9 65% evidence | 15.7/20 RS sector 20.7% · RS bench 47.8% · 1Y 126.1%11 of 12 weeks ahead 70% evidence |
| Exact sum: 17.5 + 15.9 + 6.8 + 15.7 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6LifeStance Health Group, Inc.LFST | 55.4/100Mixed-positive evidence64% evidence | LEADER | 22.4/35 Revenue 16.4% · PAT — · OPM change 5 pp 62% evidence | 5.8/25 ROCE 1.2% · OPM 5.5% 76% evidence | 8.5/20 P/E 106.2× · PEG — 15% evidence | 18.7/20 RS sector 25.5% · RS bench 51.5% · 1Y 144.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.4 + 5.8 + 8.5 + 18.7 = 55.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aveanna Healthcare Holdings Inc.AVAH | 54.4/100Thin evidence · provisional58% evidence | LEADER | 11.7/35 Revenue — · PAT — · OPM change -2.9 pp 45% evidence | 11.8/25 ROCE 4.8% · OPM 10.7% 76% evidence | 11.4/20 P/E 5.4× · PEG — 15% evidence | 19.5/20 RS sector 24.4% · RS bench 53.1% · 1Y 76%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 11.8 + 11.4 + 19.5 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8PACS Group, Inc.PACS | 53.7/100Thin evidence · provisional56% evidence | LEADER | 22.2/35 Revenue — · PAT — · OPM change 4.7 pp 39% evidence | 13.3/25 ROCE 5.2% · OPM 8.5% 76% evidence | 9.1/20 P/E 31.5× · PEG — 15% evidence | 9.1/20 RS sector -2.3% · RS bench 18.1% · 1Y 256.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 13.3 + 9.1 + 9.1 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Chemed CorporationCHE | 53.4/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.2/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence | 15.6/25 ROCE 6.6% · OPM 12.9% 76% evidence | 9.3/20 P/E 23.4× · PEG — 15% evidence | 10.3/20 RS sector -13.8% · RS bench 6.4% · 1Y 12.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 15.6 + 9.3 + 10.3 = 53.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Fresenius Medical Care AGFMS | 52.9/100Mixed-positive evidence81% evidence | ASLEEP | 21.9/35 Revenue -0.7% · PAT 43.7% · OPM change 1.5 pp 83% evidence | 11.3/25 ROCE 2.1% · OPM 11.7% 76% evidence | 15.7/20 P/E 11.9× · PEG 0.22 65% evidence | 4.0/20 RS sector -27% · RS bench -9% · 1Y -9.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 11.3 + 15.7 + 4 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Guardian Pharmacy Services, Inc.GRDN | 51.0/100Mixed-positive evidence64% evidence | TURNING | 17.6/35 Revenue 13.6% · PAT — · OPM change 1.4 pp 62% evidence | 12.3/25 ROCE 7.8% · OPM 5.3% 76% evidence | 8.7/20 P/E 45.4× · PEG — 15% evidence | 12.4/20 RS sector 3% · RS bench 25.9% · 1Y 82.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 12.3 + 8.7 + 12.4 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12HCA Healthcare, Inc.HCA | 50.9/100Mixed-positive evidence85% evidence | BREAKING OUT | 14.6/35 Revenue 7.3% · PAT 14.1% · OPM change -0.7 pp 95% evidence | 15.6/25 ROCE 6.9% · OPM 15.2% 76% evidence | 15.1/20 P/E 13.1× · PEG 0.51 65% evidence | 5.6/20 RS sector -28.6% · RS bench -10.7% · 1Y 7%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 15.6 + 15.1 + 5.6 = 50.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Healthcare Services Group, Inc.HCSG | 50.8/100Thin evidence · provisional52% evidence | FADING | 23.0/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence | 10.7/25 ROCE 3.6% · OPM 7.3% 76% evidence | 10.3/20 P/E 14.3× · PEG — 15% evidence | 6.8/20 RS sector -17.5% · RS bench 1.4% · 1Y 38.3%6 of 12 weeks ahead 70% evidence |
| Exact sum: 23 + 10.7 + 10.3 + 6.8 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14National HealthCare CorporationNHC | 48.7/100Mixed-negative evidence81% evidence | LEADER | 16.9/35 Revenue 10.3% · PAT 16.7% · OPM change 0.2 pp 83% evidence | 10.2/25 ROCE 2.5% · OPM 8.4% 76% evidence | 9.8/20 P/E 20.3× · PEG 1.48 65% evidence | 11.8/20 RS sector 2.7% · RS bench 24.7% · 1Y 92.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 10.2 + 9.8 + 11.8 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Universal Health Services, Inc.UHS | 48.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.7/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 14.0/25 ROCE 4.1% · OPM 11.2% 76% evidence | 11.3/20 P/E 6.1× · PEG — 15% evidence | 6.1/20 RS sector -29.4% · RS bench -11.2% · 1Y -3.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 14 + 11.3 + 6.1 = 48.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16agilon health, inc.AGL | 47.6/100Mixed-negative evidence61% evidence | FADING | 18.8/35 Revenue -2.8% · PAT — · OPM change 1.7 pp 62% evidence | 4.8/25 ROCE 1% · OPM 0.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.0/20 RS sector 54% · RS bench 76.9% · 1Y 209.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 4.8 + 10 + 14 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17The Pennant Group, Inc.PNTG | 46.7/100Mixed-negative evidence75% evidence | LEADER | 20.3/35 Revenue 36.6% · PAT 20.7% · OPM change 0.1 pp 83% evidence | 9.2/25 ROCE 2.3% · OPM 6.1% 76% evidence | 4.0/20 P/E 35.9× · PEG 3.03 65% evidence | 13.2/20 RS sector 1.7% · RS bench 24.3% · 1Y 76.1%11 of 12 weeks ahead 70% evidence |
| Exact sum: 20.3 + 9.2 + 4 + 13.2 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18The Ensign Group, Inc.ENSG | 45.9/100Thin evidence · provisional58% evidence | TURNING | 18.1/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 12.2/25 ROCE 2.7% · OPM 9% 76% evidence | 9.2/20 P/E 25.1× · PEG — 15% evidence | 6.4/20 RS sector -26.6% · RS bench -8.6% · 1Y 8.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 12.2 + 9.2 + 6.4 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19DaVita Inc.DVA | 45.5/100Mixed-negative evidence81% evidence | ASLEEP | 16.1/35 Revenue 6.7% · PAT -6.9% · OPM change 0.5 pp 83% evidence | 13.7/25 ROCE 3.3% · OPM 14.1% 76% evidence | 8.2/20 P/E 14.3× · PEG 2.08 65% evidence | 7.5/20 RS sector -5.3% · RS bench 14.9% · 1Y 48.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 13.7 + 8.2 + 7.5 = 45.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Pediatrix Medical Group, Inc.MD | 45.3/100Mixed-negative evidence74% evidence | LEADER | 17.7/35 Revenue -2.2% · PAT — · OPM change 1.7 pp 62% evidence | 10.1/25 ROCE 2.5% · OPM 8.7% 76% evidence | 10.0/20 P/E 10.4× · PEG 1.7 65% evidence | 7.5/20 RS sector -10.7% · RS bench 9.7% · 1Y 60.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 10.1 + 10 + 7.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Option Care Health, Inc.OPCH | 43.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change -0.5 pp 45% evidence | 11.3/25 ROCE 3.3% · OPM 5.4% 76% evidence | 9.9/20 P/E 15.8× · PEG — 15% evidence | 5.0/20 RS sector -33.3% · RS bench -16.1% · 1Y -13.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 11.3 + 9.9 + 5 = 43.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Acadia Healthcare Company, Inc.this pageACHC | 42.8/100Thin evidence · provisional58% evidence | LEADER | 15.1/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 7.5/25 ROCE 1.1% · OPM 5.8% 76% evidence | 9.5/20 P/E 21.2× · PEG — 15% evidence | 10.7/20 RS sector -5.6% · RS bench 14.9% · 1Y 27.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 7.5 + 9.5 + 10.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Select Medical Holdings CorporationSEM | 40.3/100Mixed-negative evidence75% evidence | 11.0/35 Revenue 5.8% · PAT -20% · OPM change -1.4 pp 83% evidence | 9.8/25 ROCE 2% · OPM 6.9% 76% evidence | 12.9/20 P/E 15.4× · PEG 0.93 65% evidence | 6.6/20 RS sector -23% · RS bench 1.5% · 1Y 9%0 of 1 week ahead to 2026-07-02 70% evidence | |
| Exact sum: 11 + 9.8 + 12.9 + 6.6 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Ardent Health, Inc.ARDT | 40.2/100Mixed-negative evidence65% evidence | BREAKING OUT | 14.5/35 Revenue 6.7% · PAT -26.8% · OPM change 0.6 pp 83% evidence | 8.8/25 ROCE 1.9% · OPM 5.1% 76% evidence | 10.9/20 P/E 9× · PEG — 15% evidence | 6.0/20 RS sector -21.3% · RS bench -1.8% · 1Y -16.4%8 of 12 weeks ahead 70% evidence |
| Exact sum: 14.5 + 8.8 + 10.9 + 6 = 40.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Astrana Health, Inc.ASTH | 39.7/100Mixed-negative evidence81% evidence | ASLEEP | 14.5/35 Revenue 56.8% · PAT -20.5% · OPM change -0.3 pp 83% evidence | 7.4/25 ROCE 2.2% · OPM 3% 76% evidence | 10.5/20 P/E 40.2× · PEG 1.17 65% evidence | 7.3/20 RS sector -6.8% · RS bench 13.6% · 1Y 35.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 7.4 + 10.5 + 7.3 = 39.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26InnovAge Holding Corp.INNV | 38.1/100Thin evidence · provisional58% evidence | LEADER | 10.8/35 Revenue 14.2% · PAT — · OPM change -6.8 pp 62% evidence | 3.6/25 ROCE -8.8% · OPM -11.5% 76% evidence | 8.6/20 P/E 103.8× · PEG — 15% evidence | 15.1/20 RS sector 8.9% · RS bench 31.1% · 1Y 134.3%12 of 12 weeks ahead 70% evidence |
| Exact sum: 10.8 + 3.6 + 8.6 + 15.1 = 38.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Sonida Senior Living, Inc.SNDA | 36.0/100Mixed-negative evidence64% evidence | BREAKING OUT | 13.0/35 Revenue 25.5% · PAT — · OPM change -20.5 pp 62% evidence | 3.8/25 ROCE -1.9% · OPM -23.6% 76% evidence | 11.5/20 P/E 1.9× · PEG — 15% evidence | 7.7/20 RS sector -12.4% · RS bench 7.5% · 1Y 46.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 3.8 + 11.5 + 7.7 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Surgery Partners, Inc.SGRY | 35.1/100Mixed-negative evidence61% evidence | ASLEEP | 14.2/35 Revenue 5.4% · PAT — · OPM change 0.1 pp 62% evidence | 7.2/25 ROCE 0.9% · OPM 8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.7/20 RS sector -33.9% · RS bench -17% · 1Y -35.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 7.2 + 10 + 3.7 = 35.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Brookdale Senior Living Inc.BKD | 33.5/100Adverse evidence61% evidence | ASLEEP | 17.3/35 Revenue -0.4% · PAT — · OPM change 3.2 pp 62% evidence | 5.0/25 ROCE 0.9% · OPM 6.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.2/20 RS sector -29.3% · RS bench -13.2% · 1Y 47.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 5 + 10 + 1.2 = 33.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30COMPASS Pathways plcCMPS | 48.2/100Thin evidence · provisional47% evidence | LEADER | 20.0/35 Revenue — · PAT — · OPM change — 33% evidence | 5.0/25 ROCE -12.9% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.2/20 RS sector 23.6% · RS bench 48.2% · 1Y 181.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 5 + 10 + 13.2 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Acadia Healthcare Company, Inc.'s stock price today?
Acadia Healthcare Company, Inc. trades at $28.2, +27.2% over the past year. The company is valued at $3.0 B. The stock sits at 72% of its 52-week range of $12–$35, +20.4% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 7 weeks in. — as of 17 September 2026.
What were Acadia Healthcare Company, Inc.'s latest quarterly results?
Acadia Healthcare Company, Inc. reported revenue of $0.8 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 7.8% and profit fell 100.0% year on year. Earnings per share were $0.05. The operating margin was 6.0%, 0.8 pp higher than a year earlier. — as of 17 September 2026.
What is Acadia Healthcare Company, Inc.'s revenue?
Acadia Healthcare Company, Inc. reported revenue of $0.8 B in the Mar 26 quarter, +7.8% year on year. For the full FY25 fiscal year, revenue was $3.3 B (+5.1%). Over the last 4 years revenue compounded at 9.4% a year. — as of 17 September 2026.
What is Acadia Healthcare Company, Inc.'s profit?
Acadia Healthcare Company, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −100.0% year on year. Full-year FY25 profit was $−1.1 B. The operating margin ran 6.0% in the latest quarter. — as of 17 September 2026.
What is Acadia Healthcare Company, Inc.'s market cap?
Acadia Healthcare Company, Inc.'s market capitalisation is $3.0 B at a stock price of $28.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Acadia Healthcare Company, Inc.'s P/E ratio?
Acadia Healthcare Company, Inc. trades at a P/E of 23.8×, at the 55th percentile of its own 4-year range, against a long-run median of 23.4×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Acadia Healthcare Company, Inc. pay a dividend?
No — Acadia Healthcare Company, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is Acadia Healthcare Company, Inc. overvalued?
On its own history, Acadia Healthcare Company, Inc. looks mid-range: its P/E of 23.8× sits at the 55th percentile of its 4-year range (long-run median 23.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Acadia Healthcare Company, Inc. growing?
Yes — Acadia Healthcare Company, Inc. is growing: latest-quarter revenue +7.8% year on year, profit −100.0%, and the margin +0.8 pp at 6.0%. The earnings engine currently reads: improving — as of 17 September 2026.
How is Acadia Healthcare Company, Inc. performing?
Acadia Healthcare Company, Inc. is in a confirmed uptrend, 7 weeks in. Its latest quarter's revenue rose 7.8% and profit fell 100.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 13 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Acadia Healthcare Company, Inc. in?
Deteriorating — profit and EPS growth are shrinking (profit growth −678.9% latest against −22.9% at its 12-quarter best), ROCE slipping at 4.8%. The read comes from the last 12 quarters of growth (revenue growth +6.6% latest, profit growth −678.9% latest, eps growth −703.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Acadia Healthcare Company, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 7 of stage 2), trading +20.4% versus its 200-day average and at 72% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Acadia Healthcare Company, Inc. beating the market?
On recent form, yes — Acadia Healthcare Company, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 13 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved −48% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will Acadia Healthcare Company, Inc.'s stock price go up?
This page publishes no price forecast for Acadia Healthcare Company, Inc. What it measures instead: the stock price is $28.2, the price is in a confirmed uptrend 7 weeks in. Its P/E of 23.8× sits at the 55th percentile of its own 4-year range. — as of 17 September 2026.
Is the market betting against Acadia Healthcare Company, Inc.?
Yes — short interest is 24.7% of Acadia Healthcare Company, Inc.'s tradable float, about 12.7 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Acadia Healthcare Company, Inc. have too much debt?
It carries real leverage — Acadia Healthcare Company, Inc.'s debt-to-equity is 1.18. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Acadia Healthcare Company, Inc.'s capex?
Acadia Healthcare Company, Inc. spent $2.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.6 B. — as of 17 September 2026.
What is Acadia Healthcare Company, Inc.'s cash flow?
Acadia Healthcare Company, Inc. generated $0.1 B of operating cash flow in FY25 and $−0.4 B of free cash flow after $0.6 B of capital spending. Reported profit that year was $−1.1 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Acadia Healthcare Company, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 168% of Acadia Healthcare Company, Inc.'s reported profit arrived as operating cash. Though the latest year ran at -12% — the trend is the thing to watch. In FY25, operating cash was $0.1 B against reported profit of $−1.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Acadia Healthcare Company, Inc.?
On the balance sheet, the Z-score reads 1.04 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 17 September 2026.
Where is Acadia Healthcare Company, Inc. in its business cycle?
Acadia Healthcare Company, Inc.'s FY25 operating margin was −28.1%, against a 5-year band of −28.1%–16.1%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 6.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Acadia Healthcare Company, Inc. story?
The sharpest disagreement: the price moved +27.2% in a year while annual EPS moved −537.4% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Acadia Healthcare Company, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Acadia Healthcare Company, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!